Accountable Care Organizations Public Reporting Information
FMC ACO
ACO NAME & LOCATION
Florida Medical Clinic ACO, LLC
38135 Market Square
Zephyrhills, FL 33542
ACO PRIMARY CONTACT
Chandresh Saraiya, MD, FMC
Florida Medical Clinic, LLC
Chairman
813.712.1645
ORGANIZATIONAL INFORMATION
ACO Participants
Florida Medical Clinic, LLC
FMC Urgent Care, LLC
ACO PARTICIPANTS IN JOINT VENTURES BETWEEN ACO PROFESSIONALS AND HOSPITALS
FMC Urgent Care, LLC
Florida Medical Clinic, LLC
ACO GOVERNING BODY
Juan Cevallos, MD
Voting member
ACO Participant Representative, FMC
Joe Cozzolino, MD
Voting member
ACO Participant Representative, FMC
Gerald Curley, DO
Voting member
ACO Participant Representative, FMC
Joe Delatorre, CEO
Voting member
Other representative
Emilio Dominguez, MD
Voting member
ACO Participant Representative, FMC
Mitch Forman, MD
Voting member
ACO Participant Representative, FMC Urgent Care
Joseph Gallagher
Voting member
Medicare Beneficiary Representative
Paul Gerczuk, MD
Voting member
ACO Participant Representative, FMC
Matthew Hartlage, MD
Voting member
ACO Participant Representative, FMC
Belen Herrero, MD
Voting member
ACO Participant Representative, FMC
Richard Ina, MD
Voting member
ACO Participant Representative, FMC
Chandresh Saraiya, MD
Chairman
Voting member
ACO Participant Representative, FMC
Rohitkumar Vyas, MD
Voting member
ACO Participant Representative, FMC
KEY ACO CLINICAL AND ADMINISTRATIVE LEADERSHIP
Joe Delatorre, CEO
ACO Executive
Dr. Chandresh Saraiya,
Medical Director
Eddine Luma,
Compliance & HIPAA Privacy Officer
Dr. Emilio Dominguez,
Chief Medical Director
ACO COMMITTEES & COMMITTEE LEADERSHIP
Quality and Performance Monitoring Committee
Nancy Finnerty, MD
Chairman
Douglas Baska, DO
Crete Fisher, MD
Joseph Hubaykah, MD
Tracy Mckay, MD
Richard McDonough, MD
Parag Pitroda, MD
Chandresh Saraiya, MD
Joel Sokolik, MD
Gabriel Somori, MD
Compliance Committee
Eddine Luma, Assoc. Director of Clinical Transformation & Compliance & HIPAA Privacy Officer
Chairperson
Christian Alvarez, CFO
Samantha Champagnie, Senior Director
Joe Delatorre, CEO
Emilio Dominguez, MD
Gus Taylor, CAO
Paula VanNorman, Sr. Director of Physician Offices
Community Relations Committee
Chandresh Saraiya, MD, FMC
Chairman
Leigh Walker-Blankenship, ACO Manager, FMC
Sirisha Chalasani, MD, FMC
Ana Z. Torres Alvarez, ACO RN Care Manager, FMC
Heather Tomberlin, ACO LPN Care Manager, FMC
James Judkins, ACO LPN Care Manager, FMC
Traci Belle Simpson, ACO RN Care Manager, FMC
Tanja Cogan, BSW, FMC
Evan Smith, Encompass Home Health
Alysia Dunwoody, RN, Encompass Home Health
Michael Dougherty, RN, Encompass Home Health
Kathy Kondolf-Harmmer, Administrator, Heartland of Zephyrhills
Adam Timer, Heartland of Zephyrhills
Donna Coulter, DON, Royal Oaks
Jake Mitchell, Administrator, Royal Oaks
Rosemary Hartzner, Admissions Director, Royal Oaks
Payton Baker, Heritage Park
Lido Capogrosso, Admissions Director, Heritage Park
Pamela Cafra, Zephyrhills Health & Rehab
Karen Alvarez, CARES Home Health
Rey Basila, PT, Administrator, Mission Home Care
Geri Burke, Care Patrol
Crete Fisher, MD, FMC
Reginald Villaruel, RN, Director of Nursing, Mission Home Care
Florida Medical Clinic ACO Information
ACO Information
TYPES OF ACO PARTICIPANTS THAT FORMED THE ACO
A network of individual practices of ACO professionals
Shared Savings and Losses
Amount of Shared Savings/Losses
Second Agreement Period | First Agreement Period |
Performance Year 2017, $4,615,423
Performance Year 2016, $0 |
Performance Year 2015, $0
Performance Year 2014, $0 Performance Year 2013, $0 |
Shared Savings Distribution
Second Agreement Period | First Agreement Period |
Performance Year 2017 Proportion invested in infrastructure: 10% Proportion invested in redesigned care processes/resources: 10% Proportion of distribution to ACO participants: 80% A: PCP’s 70% B: Hospitalist and Specialist 30%Performance Year 2016 Proportion invested in infrastructure: N/A Proportion invested in redesigned care processes/resources: N/A Proportion of distribution to ACO participants: N/A |
Performance Year 2015 Proportion invested in infrastructure: N/A Proportion invested in redesigned care processes/resources: N/A Proportion of distribution to ACO participants: N/APerformance Year 2014 Proportion invested in infrastructure: N/A Proportion invested in redesigned care processes/resources: N/A Proportion of distribution to ACO participants: N/APerformance Year 2013 Proportion invested in infrastructure: N/A Proportion invested in redesigned care processes/resources: N/A Proportion of distribution to ACO participants: N/A |
PAYMENT RULE WAIVERS
Yes, our ACO does use the SNF 3-Day Rule Waiver.
QUALITY PERFORMANCE RESULTS
Click here to view 2018 Quality Report PDF
Click here to view 2017 Quality Report PDF
PREVIOUS YEARS QUALITY PERFORMANCE RESULTS
2012 Reporting Period | 2013 Reporting Period | 2014 Reporting Period | |||||
Measure number | Performance Measure | ACO Performance Rate | Mean Performance Rate for All ACOs | ACO Performance Rate | Mean Performance Rate for All ACOs | ACO Performance Rate | Mean Performance Rate for All ACOs |
ACO #1 | Getting Timely Care, Appointments, and Information | 78.12 | 81.69 | 78.7 | 81.48 | 77.59 | 80.13 |
ACO #2 | How Well Your Doctors Communicate | 88.73 | 92.84 | 91.72 | 92.96 | 91.46 | 92.39 |
ACO #3 | Patients’ Rating of Doctor | 88.12 | 91.86 | 90.02 | 92.06 | 91.43 | 91.58 |
ACO #4 | Access to Specialists | 88.07 | 85.11 | 87.91 | 85.12 | 86.84 | 83.97 |
ACO #5 | Health Promotion and Education | 56.87 | 56.61 | 59.86 | 58.38 | 58.8 | 58.29 |
ACO #6 | Shared Decision Making | 72.57 | 73.99 | 75.57 | 74.53 | 75.06 | 74.6 |
ACO #7 | Health Status/Functional Status | 68.58 | 70.35 | 71.08 | 71.12 | 71.42 | 71.1 |
ACO #8 | Risk Standardized, All Condition Readmissions | 14.78 | 15.42 | 14.57 | 14.9 | 14.99 | 15.15 |
ACO #9 | ASC Admissions: COPD or Asthma in Older Adults | 0.9 | 1.13 | 1.07 | 1.17 | 0.85 | 1.08 |
ACO #10 | ASC Admission: Heart Failure | 1.33 | 1.09 | 1.26 | 1.2 | 1.26 | 1.19 |
ACO #11 | Percent of PCPs who Qualified for EHR Incentive Payment | 92.11% | 25.70% | 86.00% | 66.21% | 94.64% | 76.71% |
ACO #12 | Medication Reconciliation | 0.19 | 72.37 | 24.59 | 73.56 | 69.29 | 82.61 |
ACO #13 | Falls: Screening for Fall Risk | 2.3 | 28.27 | 45.67 | 39.57 | 58.54 | 45.6 |
ACO #14 | Influenza Immunization | 60.76 | 50.58 | 68.66 | 56.93 | 69.36 | 57.51 |
ACO #15 | Pneumococcal Vaccination | 47.39 | 48.62 | 64.82 | 54.76 | 58.01 | 55.03 |
ACO #16 | Adult Weight Screening and Follow-up | 81.04 | 53.91 | 71.29 | 61.61 | 86.2 | 66.75 |
ACO #17 | Tobacco Use Assessment and Cessation Intervention | 96.18 | 80.12 | 97.84 | 84.01 | 97.83 | 86.79 |
ACO #18 | Depression Screening | 0.23 | 22.48 | 38.75 | 31.19 | 56.2 | 39.27 |
ACO #19 | Colorectal Cancer Screening | 50.69 | 50.21 | 74.58 | 59.3 | 65.62 | 56.14 |
ACO #20 | Mammography Screening | 52.72 | 62.23 | 59.08 | 62.05 | 70.07 | 61.41 |
ACO #21 | Proportion of Adults who had blood pressure screened in past 2 years | 0 | 71.56 | 50.2 | 74.25 | 51.05 | 60.24 |
ACO #22 | Hemoglobin A1c Control (HbA1c) (<8 percent) | 80.74 | N/A | 86.33 | N/A | 82.73 | N/A |
ACO #23 | Low Density Lipoprotein (LDL) (<100 mg/dL) | 57.31 | N/A | 63.31 | N/A | N/A | N/A |
ACO #24 | Blood Pressure (BP) <140/90 | 73.09 | N/A | 74.34 | N/A | 66.91 | N/A |
ACO #25 | Tobacco Non Use | 88.86 | N/A | 90.17 | N/A | 88.08 | N/A |
ACO #26 | Asprin Use | 72.86 | N/A | 86.42 | N/A | 86.14 | N/A |
ACO #27 | Percent of Beneficiaries with Diabetes whose HbA1c in poor control (>9 percent) | 13.92% | 25.94% | 7.43% | 22.11% | 8.74% | 20.35% |
ACO #28 | Percent of Beneficiaries with Hypertension whose BP <140/90 | 71.28% | 63.22% | 80.19% | 67.79% | 64.32% | 68.02% |
ACO #29 | Percent of Beneficiaries with IVD with complete lipid profile and LDL control <100mg/dl | 59.04% | 52.02% | 64.90% | 55.44% | N/A | N/A |
ACO #30 | Percent of Beneficiaries with IVD who use Asprin ir other Antithrombotic | 79.08% | 72.60% | 84.76% | 76.35% | 86.49% | 80.79% |
ACO #31 | Beta-Blocker Therapy for LVSD | 70.83 | 79.60 | 90.79 | 79.82 | 88.89 | 82.71% |
ACO #32 | Drug Therapy for Lowering LDL Cholesterol | 78.95 | N/A | 82.41 | N/A | N/A | N/A |
ACO #33 | ACE Inhibitor or ARB Therapy for Patients with CAD and Diabetes and/or LVSD |
For more information on how to interpret scores on the above quality performance measures, see
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/sharedsavingsprogram/downloads/MSSP-QM-Benchmarks.pdf